GM-1 ganglioside administration combined with physical therapy restores ambulation in humans with chronic spinal cord injury
1993; Elsevier BV; Volume: 161; Issue: 2 Linguagem: Inglês
10.1016/0304-3940(93)90287-u
ISSN1872-7972
AutoresJudith Boas Walker, Michelle Harris,
Tópico(s)Stroke Rehabilitation and Recovery
ResumoIn a randomized double-blind cross-over study, humans with chronic spinal cord injury received ganglioside GM-1 or placebo for 2 months. GM-1, administered intravenously at a dose of 100 mg, 6 days a week, resulted in a statistically significant improvement of motor scores (P < 0.05), whether administered before or after 2 months of placebo. There was no placebo effect on motor scores. Subjects who received GM-1 before placebo maintained their improvement during the placebo phase. Subjects who received GM-1 ambulated with a reciprocal gait, using orthotics, for longer distances and at a faster rate whether the drug was administered before or after placebo. These results constitute the first finding that any chemical substance improves locomotion in human chronic spinal cord injury.
Referência(s)